GH Research PLC reported no revenue and a net loss of $15.1 million, or $0.23 per share, for the second quarter of 2026. The loss per share was smaller than the consensus analyst estimate for a loss of $0.31. The results reflect increased spending on research and development as the clinical-stage company prepares for its pivotal Phase 3 program.
Key Highlights
- Net Loss: The net loss for the second quarter widened to $15.1 million from $9.3 million in the same period last year, driven by higher operating expenses.
- R&D Investment: Research and development expenses increased to $12.4 million from $9.0 million in the prior-year quarter, primarily related to preparations for the GH001 pivotal program.
- Strong Cash Position: The company ended the quarter with $345.1 million in cash and cash equivalents, significantly bolstered by net proceeds of $111.2 million from an equity offering in April 2026.